Increased Protein Stability of CDKN1C Causes a Gain-of-Function Phenotype in Patients with IMAGe Syndrome

Mutations in the proliferating cell nuclear antigen (PCNA)-binding domain of the CDKN1C gene were recently identified in patients with IMAGe syndrome. However, loss of PCNA binding and suppression of CDKN1C monoubiquitination by IMAGe-associated mutations hardly explain the reduced-growth phenotype characteristic of IMAGe syndrome. We demonstrate here that IMAGe-associated mutations in the CDKN1C gene dramatically increased the protein stability. We identified a novel heterozygous mutation, c.815T>G (p.Ile272Ser), in the CDKN1C gene in three siblings manifesting clinical symptoms associated with IMAGe syndrome and their mother (unaffected carrier). PCNA binding to CDKN1C was disrupted in the case of p.Ile272Ser, and for two other IMAGe-associated mutations, p.Asp274Asn and p.Phe276Val. Intriguingly, the IMAGe-associated mutant CDKN1C proteins were fairly stable even in the presence of cycloheximide, whereas the wild-type protein was almost completely degraded via the proteasome pathway, as shown by the lack of degradation with addition of a proteasome inhibitor, MG132. These results thus suggested that the reduced-growth phenotype of IMAGe syndrome derives from CDKN1C gain-of-function due to IMAGe-associated mutations driving increased protein stability.

[1]  S. Nelson,et al.  Mutations in the PCNA-binding domain of CDKN1C cause IMAGE Syndrome , 2012, Nature Genetics.

[2]  E. Kipreos,et al.  Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. , 2012, Trends in cell biology.

[3]  Diana S. Johnson,et al.  IMAGe syndrome: Case report with a previously unreported feature and review of published literature , 2010, American journal of medical genetics. Part A.

[4]  T. Hunter,et al.  Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors , 2010, Cell cycle.

[5]  Shiyun Ling,et al.  14-3-3τ Regulates Ubiquitin-Independent Proteasomal Degradation of p21, a Novel Mechanism of p21 Downregulation in Breast Cancer , 2010, Molecular and Cellular Biology.

[6]  V. Gorgoulis,et al.  p57KIP2: “Kip”ing the Cell under Control , 2009, Molecular Cancer Research.

[7]  Keiji Tanaka,et al.  A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation , 2008, EMBO reports.

[8]  G. Nishimura,et al.  Radiological evolution in IMAGe association: A case report , 2008, American journal of medical genetics. Part A.

[9]  Xiao-xin Sun,et al.  MDMX Promotes Proteasomal Turnover of p21 at G1 and Early S Phases Independently of, but in Cooperation with, MDM2 , 2007, Molecular and Cellular Biology.

[10]  P. Ekert,et al.  Two sisters with IMAGe syndrome: Cytomegalic adrenal histopathology, support for autosomal recessive inheritance and literature review , 2006, American journal of medical genetics. Part A.

[11]  E. McCabe,et al.  IMAGe association and congenital adrenal hypoplasia: no disease-causing mutations found in the ACD gene. , 2006, Molecular genetics and metabolism.

[12]  P. Lapunzina,et al.  Familial occurrence of the IMAGe association: additional clinical variants and a proposed mode of inheritance. , 2005, The Journal of clinical endocrinology and metabolism.

[13]  M. Zacharin,et al.  IMAGe syndrome: a complex disorder affecting growth, adrenal and gonadal function, and skeletal development. , 2004, The Journal of pediatrics.

[14]  M. Dai,et al.  MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation , 2003, The EMBO journal.

[15]  K. Nakayama,et al.  Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Tauber,et al.  IMAGe Association: Additional Clinical Features and Evidence for Recessive Autosomal Inheritance , 2002, Hormone Research in Paediatrics.

[17]  M. Nakanishi,et al.  A degradation signal located in the C‐terminus of p21WAF1/CIP1 is a binding site for the C8 α‐subunit of the 20S proteasome , 2001, The EMBO journal.

[18]  K. Nakayama,et al.  Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation. , 2000, Journal of biochemistry.

[19]  M. Kay,et al.  IMAGe, a new clinical association of intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies. , 1999, The Journal of clinical endocrinology and metabolism.

[20]  R. DePinho,et al.  Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Elledge,et al.  Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome , 1997, Nature.

[22]  M. Barbacid,et al.  Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. , 1997, Genes & development.

[23]  Y. Fukushima,et al.  An imprinted gene p57KIP2 is mutated in Beckwith–Wiedemann syndrome , 1996, Nature Genetics.

[24]  M. Nakanishi,et al.  The C-terminal Region of p21 Is Involved in Proliferating Cell Nuclear Antigen Binding but Does Not Appear to Be Required for Growth Inhibition (*) , 1995, The Journal of Biological Chemistry.

[25]  J. Massagué,et al.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. , 1995, Genes & development.